Publications by authors named "C Wickenhauser"

Histological slides contain numerous artifacts that can significantly deteriorate the performance of image analysis algorithms. Here we develop the GrandQC tool for tissue and multi-class artifact segmentation. GrandQC allows for high-precision tissue segmentation (Dice score 0.

View Article and Find Full Text PDF

Breast cancer (BC) is a leading cause of death worldwide, particularly also among African woman. In order to better stratify patients for the most effective (immuno-) therapy, an in depth characterization of the immune status of BC patients is required. In this study, a cohort of 65 Ethiopian patients with primary BC underwent immune profiling by multicolor flow cytometry on peripheral blood samples collected prior to surgery and to any other therapy.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the long-term effects of multiple myeloma and its treatment on the immune system of cancer survivors, finding significant changes even years after being cancer-free.
  • Analysis revealed that these survivors have a compromised bone marrow environment, which is linked to ongoing inflammation and the presence of residual myeloma cells, despite the absence of detectable cancer.
  • The research suggests that initial cancer treatment leads to lasting "immunological scarring," indicating that some immune system changes may be irreversible.
View Article and Find Full Text PDF

Background: The clinical management of breast cancer (BC) is mainly based on the assessment of receptor expression by tumour cells. However, there is still an unmet need for novel biomarkers important for prognosis and therapy. The tumour immune microenvironment (TIME) is thought to play a key role in prognosis and therapy selection, therefore this study aimed to describe the TIME in Ethiopian BC patients.

View Article and Find Full Text PDF

Inhibition of the proximal B cell receptor (BCR) signaling pathway by BTK inhibitors is highly effective in the treatment of CLL, but drug resistance or intolerance occurs. Here, we investigated c-Jun N-terminal protein kinase 1 (JNK1) as an alternative drug target in the distal BCR pathway. JNK1 was preferentially overexpressed and activated in poor prognostic CLL with unmutated IGHV.

View Article and Find Full Text PDF